AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10780154 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centered group psychotherapy (twice a week, approximately 100 sessions)
Number of subjects: 43
Study 10780154 — intervention group
Group type: COMPARATOR
Intervention: Clinical standard treatment (control group)
Number of subjects: 43
Study 8831655 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week, four-session group intervention
Number of subjects: 145
Study 8831655 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 71)
Number of subjects: 145
Study 8831655 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed subjects receiving the intervention
Number of subjects: 145
Study 8831655 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondepressed subjects receiving the intervention
Number of subjects: 145
Study 1306004 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-glucuronylglucosaminoglycane combination
Number of subjects: 20
Study 1306004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3743977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponsky‐Gauderer gastrostomy kit
Number of subjects: 0
Study 3743977 — intervention group
Group type: EXPERIMENTAL
Intervention: Sachs‐Vine gastrostomy kit
Number of subjects: 0
Study 3743977 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgically placed gastrostomy
Number of subjects: 0
Study 29380190 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated closed-loop goal-directed fluid therapy
Number of subjects: 46
Study 29380190 — intervention group
Group type: COMPARATOR
Intervention: Manual fluid administration (control)
Number of subjects: 46
Study 27399350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nω‐hydroxy‐nor‐L‐arginine (arginase inhibitor)
Number of subjects: 12
Study 27399350 — intervention group
Group type: COMPARATOR
Intervention: Healthy age‐matched control subjects (n = 12)
Number of subjects: 12
Study 27399350 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with type 2 diabetes
Number of subjects: 12
Study 25006989 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharopeptide from Trametes versicolor (PSP)
Number of subjects: 24
Study 25006989 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 24
Study 25006989 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 24
Study 22649517 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype score based on weighted risk alleles regarding low serum 25(OH)D levels
Number of subjects: 9528
Study 22649517 — intervention group
Group type: EXPERIMENTAL
Intervention: rs6013897 genotypes (CYP24A1)
Number of subjects: 9528
Study 20397499 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia ceramic post with composite core (Group B)
Number of subjects: 0
Study 20397499 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber composite post with composite core (Group C)
Number of subjects: 0
Study 20397499 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium post with composite core (Group D)
Number of subjects: 0
Study 20397499 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia ceramic post with composite core (Group B) with TSC
Number of subjects: 0
Study 20397499 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass FRC post with composite core (Group C) with TSC
Number of subjects: 0
Study 20397499 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia ceramic post with glass-ceramic core (Group A)
Number of subjects: 0
Study 20397499 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups E, F, G, and H (same post-and-core materials as Groups A-D without TSC)
Number of subjects: 0
Study 18234424 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim) 5 mcg/kg/day
Number of subjects: 172
Study 18234424 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim) 10 mcg/kg/day
Number of subjects: 172
Study 18234424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensified AC followed by T
Number of subjects: 172
Study 19258625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 0
Study 19258625 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise
Number of subjects: 0
Study 15572993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar stabilisation exercise training (10-week programme)
Number of subjects: 41
Study 15572993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study 11223696 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha(1)‐Adrenoceptor antagonists such as tamsulosin
Number of subjects: 0
Study 11223696 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha(1A)‐adrenoceptor blockade
Number of subjects: 0
Study 11223696 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha(1D) and alpha(1A)‐adrenoceptor blockade
Number of subjects: 0
Study 11223696 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with alpha-blockers
Number of subjects: 0
Study 11223696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with alpha-blockers
Number of subjects: 0
Study 9137507 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐galactose (1.9 g/kg BW per day)
Number of subjects: 80
Study 9137507 — intervention group
Group type: COMPARATOR
Intervention: D‐glucose‐containing electrolyte infusions
Number of subjects: 80
Study 8195583 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 42
Study 8195583 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 42
Study 3300175 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion therapy (CSII)
Number of subjects: 65
Study 3300175 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection treatment (CIT)
Number of subjects: 65
Study 31888699 — intervention group
Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) administered to the motor cortex (M1) or dorso lateral prefrontal cortex (DLPFC) for 10 sessions over 4 weeks at 2 mA for 20 minutes.
Number of subjects: 45
Study 31888699 — intervention group
Group type: COMPARATOR
Intervention: Sham group receiving no active tDCS treatment.
Number of subjects: 45
Study 28844214 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile ointment
Number of subjects: 40
Study 28844214 — intervention group
Group type: COMPARATOR
Intervention: Lanoline (placebo)
Number of subjects: 40
Study 26507452 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel technique + Acellular Dermal Matrix (TUN+ADM)
Number of subjects: 20
Study 26507452 — intervention group
Group type: COMPARATOR
Intervention: Coronally Advanced Flap + Acellular Dermal Matrix (CAF+ADM)
Number of subjects: 20
Study 23429642 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for 5 days
Number of subjects: 24
Study 23429642 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir 800 mg three times daily for 5 days
Number of subjects: 24
Study 23429642 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily + Boceprevir 800 mg three times daily for 5 days
Number of subjects: 24
Study 21864856 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdrive biatrial pacing at a rate of 80 pulses per minute for 5 days
Number of subjects: 100
Study 21864856 — intervention group
Group type: COMPARATOR
Intervention: Control group without pacing
Number of subjects: 100
Study 21864856 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdrive biatrial pacing
Number of subjects: 100
Study 19214886 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE)
Number of subjects: 57
Study 16729287 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg MRA/kg body weight
Number of subjects: 29
Study 16729287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15616416 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg) for 4 weeks
Number of subjects: 34
Study 15616416 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 34
Study 15616416 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and placebo
Number of subjects: 34
Study 11207873 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0
Study 11207873 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective estrogen receptor modulators
Number of subjects: 0
Study 11207873 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen replacement therapy
Number of subjects: 0
Study 11207873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9218932 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca-Cola (325 ml) with 100 mg itraconazole
Number of subjects: 8
Study 9218932 — intervention group
Group type: COMPARATOR
Intervention: Water (325 ml) with 100 mg itraconazole
Number of subjects: 8
Study 7963418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 38
Study 7963418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3478276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-cervical 15-Me PGF2 alpha gel
Number of subjects: 42
Study 3478276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 gel
Number of subjects: 42
Study 3478276 — intervention group
Group type: COMPARATOR
Intervention: Intra-cervical gel alone (placebo)
Number of subjects: 42
Study 30007113 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned caesarean
Number of subjects: 2305
Study 30007113 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal birth
Number of subjects: 2305
Study 26657005 — intervention group
Group type: EXPERIMENTAL
Intervention: Price subsidy + health education (PS+HE) group
Number of subjects: 2567
Study 26657005 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education (HE) only group
Number of subjects: 2567
Study 26657005 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2567
Study 26657005 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt sales survey
Number of subjects: 2567
Study 23878011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative external head-cooling technique (Group H)
Number of subjects: 50
Study 23878011 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (CPB) only (Group C)
Number of subjects: 50
Study 23878011 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature during aortic cross-clamp period
Number of subjects: 50
Study 22777320 — intervention group
Group type: EXPERIMENTAL
Intervention: MDC group (n=23)
Number of subjects: 78
Study 22777320 — intervention group
Group type: COMPARATOR
Intervention: SRCC/PDC group (n=55)
Number of subjects: 78
Study 22777320 — intervention group
Group type: COMPARATOR
Intervention: D1 dissection (n=23)
Number of subjects: 78
Study 19729984 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG)
Number of subjects: 116
Study 19729984 — intervention group
Group type: EXPERIMENTAL
Intervention: Graves' orbitopathy (GO) with ocular hypertension (OHT)
Number of subjects: 116
Study 19729984 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy eyes)
Number of subjects: 116
Study 17851701 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral lumbar spinal fusion with pedicle screw instrumentation
Number of subjects: 107
Study 17851701 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral lumbar spinal fusion without pedicle screw instrumentation
Number of subjects: 107
Study 16989163 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Hymenoptera venom
Number of subjects: 32
Study 16989163 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with allergy to other allergens)
Number of subjects: 32
Study 14748646 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted question recasts (30 recasts with auxiliary is and 30 with modal will) during twenty 30‐min enrichment sessions over a 2‐month period.
Number of subjects: 34
Study 14748646 — intervention group
Group type: COMPARATOR
Intervention: Play sessions without exposure to inverted is and will questions.
Number of subjects: 34
Study 9799143 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind approach (V group)
Number of subjects: 150
Study 9799143 — intervention group
Group type: COMPARATOR
Intervention: Open approach (H group)
Number of subjects: 150
Study 9799143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 8135387 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate
Number of subjects: 60
Study 8135387 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl
Number of subjects: 60
Study 8135387 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam
Number of subjects: 60
Study 8135387 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol
Number of subjects: 60
Study 8135387 — intervention group
Group type: EXPERIMENTAL
Intervention: thiopental
Number of subjects: 60
Study 8135387 — intervention group
Group type: COMPARATOR
Intervention: isoflurane
Number of subjects: 60
Study 2807362 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 20
Study 2807362 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20
Study 2807362 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 20
Study 4616806 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethiazole (500 mg in 10 ml dose)
Number of subjects: 68
Study 4616806 — intervention group
Group type: COMPARATOR
Intervention: Nitrazepam (10 mg single dose)
Number of subjects: 68
Study 4616806 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of treatment
Number of subjects: 68
Study 31419313 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment: 18 months of teriparatide followed by 18 months of denosumab
Number of subjects: 70
Study 31419313 — intervention group
Group type: COMPARATOR
Intervention: Cyclic treatment: three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab
Number of subjects: 70
Study 31419313 — intervention group
Group type: COMPARATOR
Intervention: Cyclic treatment
Number of subjects: 70
Study 30583667 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation based on Health Belief Model (4 weekly sessions)
Number of subjects: 150
Study 26700457 — intervention group
Group type: COMPARATOR
Intervention: saline (0.9 mL)
Number of subjects: 11
Study 26700457 — intervention group
Group type: EXPERIMENTAL
Intervention: capsaicin (3 mg in 0.2 mL saline with 7% Tween 80)
Number of subjects: 11
Study 26700457 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (10 mg kg(‐1))
Number of subjects: 11
Study 26700457 — intervention group
Group type: EXPERIMENTAL
Intervention: butorphanol (10 mg kg(‐1))
Number of subjects: 11
Study 24844728 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional stimulation
Number of subjects: 13
Study 24844728 — intervention group
Group type: COMPARATOR
Intervention: Omnidirectional stimulation
Number of subjects: 13
Study 22222293 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Focus intervention group
Number of subjects: 0
Study 20589920 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenges
Number of subjects: 40
Study 20589920 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 40
Study 18342923 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 2
Study 18342923 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 2
Study 18342923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 2
Study 15685543 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated-interferon (PEG-IFN) alfa-2a + ribavirin
Number of subjects: 27
Study 15685543 — intervention group
Group type: COMPARATOR
Intervention: IFN alfa-2a + ribavirin
Number of subjects: 27
Study 15685543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 27
Study 12786834 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% fusidic acid plus 0.1% betamethasone cream
Number of subjects: 46
Study 12786834 — intervention group
Group type: COMPARATOR
Intervention: Topical 2% mupirocin and 0.1% betamethasone cream
Number of subjects: 46
Study 11198658 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg base/kg plus artesunate 4 mg/kg per day for 3 days (MAS3)
Number of subjects: 108
Study 11198658 — intervention group
Group type: COMPARATOR
Intervention: Quinine (10 mg salt/kg every 8 h) for 7 days (Q7)
Number of subjects: 108
Study 11198658 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine plus artesunate (MAS3)
Number of subjects: 108
Study 11198658 — intervention group
Group type: COMPARATOR
Intervention: Quinine (Q7)
Number of subjects: 108
Study 9384466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 48-8684 (0.1-0.3-1 mg and 1-3-10 mg doses)
Number of subjects: 10
Study 9384466 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.1 mg(‐1) kg)
Number of subjects: 10
Study 9384466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 48-8684
Number of subjects: 10
Study 9384466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 48-8684 (10 mg)
Number of subjects: 10
Study 9384466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 48-8684 (doses increasing from 1 to 10 mg)
Number of subjects: 10
Study 9384466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 61-2466 (metabolite of Ro 48-8684)
Number of subjects: 10
Study 1553112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 34
Study 1553112 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin
Number of subjects: 34
Study 3902475 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 3902475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30067140 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoSep device
Number of subjects: 54
Study 30067140 — intervention group
Group type: COMPARATOR
Intervention: Conventional cell salvage (control)
Number of subjects: 54
Study 29519953 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8
Study 29519953 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 8
Study 29519953 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 8
Study 29519953 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 8
Study 25982391 — intervention group
Group type: EXPERIMENTAL
Intervention: Hop tablets for 12 weeks
Number of subjects: 120
Study 25982391 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for 12 weeks
Number of subjects: 120
Study 24456059 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental enrichment (EE) for 2 hours daily starting 24 hours post-injury
Number of subjects: 7
Study 24456059 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (Sim) for 2 hours daily starting 24 hours post-injury
Number of subjects: 7
Study 24456059 — intervention group
Group type: COMPARATOR
Intervention: Sham group receiving saline for 14 days post-injury
Number of subjects: 7
Study 22863900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 179
Study 20598958 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercises
Number of subjects: 22
Study 20598958 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercises
Number of subjects: 22
Study 18044283 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (group D, n=100)
Number of subjects: 300
Study 18044283 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S, n=100)
Number of subjects: 300
Study 18044283 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P, n=100)
Number of subjects: 300
Study 18044283 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study 16042674 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (4 mg day(‐1))
Number of subjects: 8
Study 16042674 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (40 mg day(‐1))
Number of subjects: 8
Study 16042674 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 8
Study 11240504 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour expectancy group
Number of subjects: 713
Study 11240504 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour expectancy group
Number of subjects: 713
Study 11240504 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour expectancy group
Number of subjects: 713
Study 9299823 — intervention group
Group type: EXPERIMENTAL
Intervention: Children under the age of two years
Number of subjects: 0
Study 9299823 — intervention group
Group type: EXPERIMENTAL
Intervention: Children from poorer households
Number of subjects: 0
Study 9299823 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with lack of running water, latrine, radio, or television in the household
Number of subjects: 0
Study 9299823 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with illiterate parents
Number of subjects: 0
Study 9299823 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed children in the first two years of life
Number of subjects: 0
Study 9299823 — intervention group
Group type: EXPERIMENTAL
Intervention: Children during the dry months of the year
Number of subjects: 0
Study 8175622 — intervention group
Group type: EXPERIMENTAL
Intervention: T+K-Placebo (T group)
Number of subjects: 55
Study 8175622 — intervention group
Group type: EXPERIMENTAL
Intervention: T+K (T+K group)
Number of subjects: 55
Study 8175622 — intervention group
Group type: EXPERIMENTAL
Intervention: half-dose T+K (T/2 + K group)
Number of subjects: 55
Study 8175622 — intervention group
Group type: COMPARATOR
Intervention: Placebo of both T and K (P group)
Number of subjects: 55
Study 2953870 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex (sustained-release luteinizing hormone-releasing hormone analogue) administered by subcutaneous injection every 28 days
Number of subjects: 46
Study 2383925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of 50 mU of biosynthetic human growth hormone (b‐hGH)
Number of subjects: 10
Study 2383925 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of somatostatin (1‐14)
Number of subjects: 10